Neocis, a company at the forefront of transforming implant dentistry, has secured $20.0 million in new funding from investors. The company is widely recognized as the manufacturer of Yomi, the only FDA-cleared robotic device specifically designed for dental surgery. This significant investment round underscores strong confidence in Neocis's innovative approach to advancing patient care and improving surgical precision through its proprietary robotic technology, which has already made a notable impact in the dental field.
The newly raised capital will be strategically deployed to accelerate Neocis's ongoing product development initiatives and significantly expand its market presence. Neocis works closely with leading clinicians to better understand their evolving needs and address complex treatment challenges in dental surgery. This funding round is crucial as it provides the necessary resources to further enhance the capabilities of the Yomi system, ensuring it continues to meet the high standards required by dental professionals and ultimately benefits a wider network of patients seeking advanced dental implant solutions.
Committed to developing innovative technologies and approaches, Neocis aims to improve the quality of life for patients undergoing dental implant procedures by making advanced robotic assistance more accessible and precise. The company, which holds an A+ rating from the Better Business Bureau, plans to leverage this investment to continue its trajectory of growth, fostering further advancements in robotic-assisted dental surgery and solidifying its position as a leader in the field. This funding is expected to support Neocis's long-term vision for innovation, expansion into new markets, and continued dedication to improving outcomes in the global dental industry.
